Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{204861,
        author = {Indrayani Satpute and Prof. Vinayak S Munde},
        title = {Design, Development, and Evaluation of a Pulsatile Drug Delivery System for Rimegepant},
        journal = {International Journal of Innovative Research in Technology},
        year = {2026},
        volume = {13},
        number = {1},
        pages = {4261-4267},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=204861},
        abstract = {Pulsatile drug delivery systems (PDDS) are advanced controlled release platforms engineered to release an active pharmaceutical ingredient (API) after a predetermined lag time, followed by a rapid drug release phase. This time specific release pattern is advantageous for conditions that follow circadian rhythms or require drug action at specific physiological times. Rimegepant is a small molecule calcitonin gene related peptide (CGRP) receptor antagonist used in the acute and preventive treatment of migraine, where immediate and timely release could enhance therapeutic outcomes. This review synthesizes existing pulsatile delivery methodologies with rimegepant’s pharmacological properties and discusses potential formulation strategies, design considerations, and evaluation criteria for future PDDS of rimegepant.},
        keywords = {Pulsatile drug delivery systems, Rimegepant, Mechanism of PDDS, Rationale for Pulsatile Delivery of Rimegepant.},
        month = {June},
        }